GlassScriptPhysician profile
Hamid S Shaaban
NPI 1578854618
$4,658.58
in general payments reported to CMS, 2019-2025
37 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $68.69 · 2021: $569 · 2022: $223 · 2023: $588 · 2024: $1,966 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.02 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $323.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,490.85 | 2019-2025 | |
| Incyte Corporation | $491.56 | 2021-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $465.27 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Daiichi Sankyo INC. | $287.92 | 2020-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $178.96 | 2021-2025 | Darzalex, Talvey, Rybrevant |
| Glaxosmithkline, LLC. | $168.07 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $154.18 | 2022-2025 | |
| Pfizer INC. | $144.59 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $121.32 | 2019-2025 | Keytruda, Lynparza |
| Seagen INC. | $99.99 | 2023 | |
| Celgene Corporation | $81.93 | 2022-2024 | Pomalyst, Reblozyl |
| Taiho Oncology, INC. | $80.46 | 2024-2025 | |
| Siemens Medical Solutions USA, INC. | $80.15 | 2021 | |
| Amgen INC. | $79.49 | 2019-2023 | Nplate, Vectibix, Xgeva |
| E.R. Squibb & Sons, L.L.C. | $74.10 | 2019-2024 | Opdivo |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Shaaban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.